Pfizer Reports Exit and Disposal Costs

Ticker: PFE · Form: 8-K · Filed: 2024-05-22T00:00:00.000Z

Sentiment: neutral

Topics: restructuring, disposal, 8-K

Related Tickers: PFE

TL;DR

Pfizer's filing an 8-K for exit/disposal costs - likely restructuring.

AI Summary

On May 22, 2024, Pfizer Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify any dollar amounts or specific dates for these activities, but it indicates a formal reporting of these costs.

Why It Matters

This filing signals that Pfizer is undergoing restructuring or divesting certain assets, which could impact future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Disposal activities can indicate financial strain or strategic shifts that may carry inherent risks for investors.

Key Players & Entities

FAQ

What specific exit or disposal activities is Pfizer reporting?

The filing does not specify the nature of the exit or disposal activities, only that costs are associated with them.

Are there any financial figures associated with these costs in the filing?

No specific dollar amounts for the exit or disposal costs are provided in this 8-K filing.

When were these exit or disposal activities initiated or reported?

The filing is dated May 22, 2024, and reports costs associated with exit or disposal activities as of that date.

What is the primary purpose of this 8-K filing for Pfizer?

The purpose is to report on costs associated with exit or disposal activities, as required by SEC regulations.

Does this filing indicate any divestitures or significant restructuring by Pfizer?

While the filing mentions 'Cost Associated with Exit or Disposal Activities,' it does not explicitly state whether these are divestitures or restructuring.

From the Filing

0000078003-24-000113.txt : 20240522 0000078003-24-000113.hdr.sgml : 20240522 20240522123937 ACCESSION NUMBER: 0000078003-24-000113 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities FILED AS OF DATE: 20240522 DATE AS OF CHANGE: 20240522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 24972633 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240522.htm 8-K MAY 22, 2024 pfe-20240522 0000078003 false 0000078003 2024-05-22 2024-05-22 0000078003 us-gaap:CommonStockMember 2024-05-22 2024-05-22 0000078003 pfe:NotesDue20271.000Member 2024-05-22 2024-05-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 22, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 2.05 Costs Associated with Exit or Disposal Activities In the second quarter of 2024, Pfizer announced it is launching a multi-year program to reduce our cost of goods sold. This cost reduction program (the “program”) will span multiple years, and is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. Given the complexity in manufacturing and longer lead times required to make changes, this program will be a multi-phased effort. The first phase of the program is focused on operational efficiencies and is expected to deliver savi

View on Read The Filing